Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

Open access
Pal, Sumanta K., Rosenberg, Jonathan E., Hoffman-Censits, Jean H., Berger, Raanan, Quinn, David I., Galsky, Matthew D., Wolf, Juergen, Dittrich, Christian, Keam, Bhumsuk, Delord, Jean-Pierre, Schellens, Jan H.M., Gravis, Gwenaelle, Medioni, Jacques, Maroto, Pablo, Sriuranpong, Virote, Charoentum, Chaiyut, Burris, Howard A., Grünwald, Viktor, Petrylak, Daniel, Vaishampayan, Ulka, Gez, Eliahu, De Giorgi, Ugo, Lee, Jae-Lyun, Voortman, Jens, Gupta, Sumati, Sharma, Sunil, Mortazavi, Amir, Vaughn, David J., Isaacs, Randi, Parker, Katie, Chen, Xueying, Yu, Kun, Porter, Dale, Graus Porta, Diana, Bajorin, Dean F.·2018·Cancer Discovery

Abstract

BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. The primary endpoint was the response rate. Among 67 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%. The most common treatment-emergent toxicities were hyperphosphatemia, elevated creatinine, fatigue, constipation, and decreased appetite. Further examination of BGJ398 in this disease setting is warranted. Significance: BJG398 is active in patients with alterations in FGFR3, resulting in both reductions in tumor volume and stabilization of disease. Our data highlight putative mechanisms of resistance to the agent, which may be useful in following disease status. Cancer Discov; 8(7); 812–21. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 781

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-18-0229

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 258

Metadata

Authors
Pal, S. K., Rosenberg, J. E., Hoffman-Censits, J. H., Berger, R., Quinn, D. I., Galsky, M. D., Wolf, J., Dittrich, C., Keam, B., Delord, J.-P., Schellens, J. H. M., Gravis, G., Medioni, J., Maroto, P., Sriuranpong, V., Charoentum, C., Burris, H. A., Grünwald, V., Petrylak, D., Vaishampayan, U., Gez, E., De Giorgi, U., Lee, J.-L., Voortman, J., Gupta, S., Sharma, S., Mortazavi, A., Vaughn, D. J., Isaacs, R., Parker, K., Chen, X., Yu, K., Porter, D., Graus Porta, D., & Bajorin, D. F.
Venue
Cancer Discovery
Published
2018-07-01
Volume
8
Issue
7
Pages
812-821
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2805915033
Cited by
258
References
32
FWCI
33.93
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. https://app.cochat.ai/papers/10.1158/2159-8290.cd-18-0229
The paper
Pal, S. K., Rosenberg, J. E., Hoffman-Censits, J. H., Berger, R., Quinn, D. I., Galsky, M. D., Wolf, J., Dittrich, C., Keam, B., Delord, J.-P., Schellens, J. H. M., Gravis, G., Medioni, J., Maroto, P., Sriuranpong, V., Charoentum, C., Burris, H. A., Grünwald, V., Petrylak, D., . . . Bajorin, D. F. (2018). Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-18-0229

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.